⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 8, 2023Expert Opinion on Drug Safety

A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

www.clinicaltrials.gov identifiers are NCT03399370, NCT03397121, NCT03400800, and NCT02597127.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dutta et al. (2023) studied this question.

synapsesocial.com/papers/69dcffbde3a90a2e2f133641 https://doi.org/10.1080/14740338.2023.2293201

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized studyRCT · 2022 · 13 citations
2Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseRCT · 2017 · 6,209 citations
3Inclisiran: A New Promising Agent in the Management of HypercholesterolemiaReview · 2018 · 101 citations
4Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol LevelsRCT · 2019 · 172 citations
5RoB 2: a revised tool for assessing risk of bias in randomised trialsSystematic Review · 2019 · 33,643 citations